

## F 1

. . . . \*

,

= Abstract =

# A Case of Group F Streptococcal Bacteremia in MPGN Patient

Ji-Young Chung, M.D., Soon-Chung Moon, M.D., Byoung-Su Cho, M.D.  
Seong-Ho Cha, M.D. and Hee-Joo Lee, M.D.\*

*Department of Pediatrics and Clinical Pathology\*, College of Medicine,  
Kyunghee University, Seoul, Korea*

*Streptococcus milleri* Group Bacteria(SMG) comprise three species, *Streptococcus anginosus*, *Streptococcus intermedius*, *Streptococcus constellatus*. Although they are commensal organism, they can be pathogenic. SMG can be aggressive pathogen in the head and neck with a propensity for abscess formation and local extension of the infection. SMG is culturally and biochemically variable, which makes it hard for the clinicians to recognize it. Hence, it seems that this organism has been relatively neglected. Most of the Lancefield F streptococci are SMG. We report one patient who had Group F streptococcal bacteremia and subdural abscess. According to his medical history, he was diagnosed as membranoproliferative glomerulonephritis three years ago. He complained headache although he was treated by appropriate antibiotics. Brain CT was used as a tool to identify the brain abscess. He had surgical drainage and was treated with IV antibiotics postoperatively.

**Key Words :** *Streptococcus milleri* Group Bacteria(SMG), Lancefield group F

<sup>1)</sup>.

(membranopro-

liferative glomerulonephritis, MPGN)

Lancefield F *Streptococcus mil-* F  
*leri* Group Bacteria(SMG) , 1  
(abscess) .

, , ,

.

: , 17 ,  
: ,  
E-mail : tcha0319@netsgo.com : 17 99 1

1 (MPGN type I) 2  
 , 1  
 ,  
 : 157 cm,  
 41 kg  
 ,  
 :  
 9,700/mm<sup>3</sup> ( 93.1%), 12.3 g/dL,  
 256,000/mm<sup>3</sup>, ESR 30 mm/hr, GOT/GPT 21/21  
 IU/L, 76 mg/dL, BUN/Cr 13/1.0 mg/dL ,  
 ASO 78 IU/ml, 3+ ,  
 300 mg/dL, many/HPF, 21 25/  
 HPF  
 X-  
 (Table 1)  
 가  
 15  
 ,  
 (Fig. 1).

F penicil-  
 lin, ceftriaxone, vancomycin, teicoplanin

peni-  
 cillin

가  
 5

ceftriaxone

. 8

F

ceftriaxone

ceftriaxone

Table 1. Cerebrospinal Fluid Examination

	HD1	HD5	HD15
RBC(/mm <sup>3</sup> )	2	0	30
WBC(/mm <sup>3</sup> )	1	30	900
Glucose(mg/dL)	62	66	54
Protein(mg/dL)	112	44	111
Culture	No growth	No growth	No growth



Fig. 1. Brain CT shows subdural effusion of left parietal and left frontal lobe.

15

teicoplanin ceftriaxone 3

*Streptococcus milleri* 1956 Guthoof가

hemolytic streptococcus)

<sup>1)</sup>. *Streptococcus milleri* Group(SMG)

(phenotype)

*Streptococcus* MG, the minute-colony forming streptococci of Lancefield group F and G, *Streptococcus intermedius*, *Streptococcus anginosus*<sup>2, 3)</sup>.

가<sup>1)</sup>.

SMG *Streptococcus viridans* 16S ribosomal RNA subunit *S. anginosus*, *S. constellatus*, *S. intermedius* 3 (species)<sup>1, 2)</sup>, -glucosidase, -galactosidase, hyaluronidase<sup>2, 4)</sup>.

SMG (commensal organism) (abscess), (local extension)<sup>1, 5)</sup>.

26.3%<sup>1, 6)</sup>. 1977 Centers for Disease Control *S. milleri*가 *S. viridans* 가

71%, 40%, 34%<sup>1, 7)</sup>. SMG 1/4 Lancefield group A, C, F G Lancefield SMG<sup>8, 9)</sup> Lancefield

group F (sensitivity) 47.3%, (specificity) 100% SMG<sup>9)</sup> F SMG<sup>1, 9)</sup>.

C, G SMG -D-glucuronide SMG가 C, G . A SMG가 bacitracin *Streptococcus pyogenes*

<sup>8)</sup> *S. anginosus*

, *S. constellatus*

*S. intermedius*

<sup>1)</sup>.

Claridge JE 3rd *S. anginosus* 19%, *S. constellatus* 73%, *S. intermedius* 86%가<sup>10)</sup>. SMG *S. interme-*dius가 가 , 가

<sup>10)</sup>. (abscess formation) (vital structure) 가

가 , 가 SMG<sup>1)</sup>. SMG ,

가<sup>1)</sup>. SMG , SMG<sup>1)</sup>. SMG 5 10% CO<sub>2</sub> 24 48<sup>1)</sup>.

5% CO<sub>2</sub> 24<sup>3)</sup>. , F

, F

가 SMG

SMG 가

SMG<sup>1, 7)</sup> Han JK penicillin

*S. intermedius* penicillin 1996 97.6% 1999 93% . ce-  
fotaxime, vancomycin, teicoplanin

100% . *S. constellatus* cefotaxime 1996 100% 1999 96.9%<sup>1)</sup>.

*Streptococcus milleri* Group Bacteria(SMG)

SMG

- 1, 3, 7, 9)
- 1) Han JK, Kerschner JE. *Streptococcus milleri* : an organism for head and neck infections and abscess. Arch Otolaryngol Head Neck Surg 2001;127:650-4.
- 2) Whiley RA, Fraser H, Hardie JM, Beighton D. Phenotypic differentiation of *Streptococcus intermedius*, *Streptococcus constellatus*, and *Streptococcus anginosus* strains within the "*Streptococcus milleri* group". J Clin Microbiol 1990;28:1497-501.
- 3) Whitworth JM. Lancefield group F and related streptococci. J Med Microbiol 1990;33:135-51.
- 4) Clarridge JE 3rd, Osting C, Jalali M, Osborne J, Waddington M. Genotypic and phenotypic characterization of "*Streptococcus milleri*" group isolates from a Veterans Administration hospital population. J Clin Microbiol 1999;37:3681-7.
- 5) Libertin CR, Hermans PE, Washington JA 2nd. Beta-Hemolytic group F *Streptococcal Bacteremia* : A study and review of the literature. Rev Infect Dis 1985;7:498-503.
- 6) Jacobs JA, Pietersen HG, Stobberingh EE, Soeters PB. Bacteremia involving the "*Streptococcus milleri*" group : analysis of 19 cases. Clin Infect Dis 1994;19:704-13.
- 7) Facklam RR. Physiological differentiation of viridans streptococci. J Clin Microbiol 1977;5:184-201.
- 8) Cooke RP, O'Neill WA. Laboratory identification of *Streptococcus milleri*. J Clin Pathol 1998;51:174.
- 9) Brogen O, Malone J, Fox C, Whyte AS. Lancefield grouping and smell of caramel for presumptive identification and assesment of pathogenicity in the *Streptococcus milleri* group. J Clin Pathol 1997;50:332-5.
- 10) Claridge JE 3rd, Attorri S, Musher DM, Hebert J, Dunbar S. *Streptococcus intermedius*, *Streptococcus constellatus*, and *Streptococcus anginosus*("Streptococcus milleri group") are of different clinical importance and are not equally associated with abscess. Clin Infect Dis 2001;32:1511-5.